Dextromethadone

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD	2023/08/25	NCT06011577	Phase 3	Terminated	Relmada Therapeutics, Inc.
Individual Patient Esmethadone (REL-1017) Expanded Access Program	2023/08/24	NCT06009003	N/A	TEMPORARILY_NOT_AVAILABLE	Relmada Therapeutics, Inc.
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)	2021/10/18	NCT05081167	Phase 3	Completed	Relmada Therapeutics, Inc.
Safety of REL-1017 for Major Depressive Disorder	2021/04/22	NCT04855760	Phase 3	Completed	Relmada Therapeutics, Inc.
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)	2021/04/22	NCT04855747	Phase 3	Terminated	Relmada Therapeutics, Inc.
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)	2020/12/29	NCT04688164	Phase 3	Completed	Relmada Therapeutics, Inc.
A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo	2019/10/30	NCT04145674	Phase 2	Recruiting	Mauro Manconi
Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)	2018/08/20	NCT03637361	Phase 1	Completed	Relmada Therapeutics, Inc.
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)	2018/08/20	NCT03638869	Phase 1	Completed	Relmada Therapeutics, Inc.
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD	2017/02/13	NCT03051256	Phase 2	Completed	Relmada Therapeutics, Inc.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Major Depressive Disorder Pipeline Advances with 75+ Companies Developing Novel Therapies

2 months ago

A comprehensive pipeline report reveals over 75 companies are developing innovative treatments for major depressive disorder, with several promising candidates advancing through Phase III trials.

12-Month Study Shows Promising Safety and Efficacy of Esmethadone for Major Depression

5 months ago

A large-scale 12-month open-label study demonstrates sustained antidepressant effects of esmethadone, a novel NMDAR antagonist, in patients with major depressive disorder.

Relmada Therapeutics Halts REL-1017 Depression Trials, Explores Strategic Alternatives

7 months ago

Relmada Therapeutics discontinues Phase 3 trials (RELIANCE II and RELIGHT) of REL-1017 for depression after unfavorable data monitoring committee evaluation.

Relmada's Phase 3 Trial of REL-1017 for Major Depressive Disorder Fails Interim Analysis

7 months ago

Relmada Therapeutics' Phase 3 Reliance II trial of REL-1017 as an adjunctive treatment for major depressive disorder is unlikely to meet its primary efficacy endpoint.

Relmada Therapeutics Anticipates Key Interim Analysis for REL-1017 in MDD

8 months ago

Relmada Therapeutics is advancing REL-1017 for major depressive disorder (MDD), with interim analysis results expected by the end of 2024.

AI-Powered Research

Premium Access

Dextromethadone

Overview

Indication

Associated Conditions